A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria

NCT07316114

Status	RECRUITING
Sponsor	Sanofi
Enrollment	400 participants

Key Eligibility Criteria

Inclusion (4)

- Patients aged 12 years or older at the time of informed consent/assent.
- Physician decision to treat the patient with dupilumab for chronic spontaneous urticaria (CSU) made prior to and independently of the patient's participation in the study.
- Patient is able to understand and complete study-related questionnaires.
- Patients and/or parent/legally authorized representative provide voluntary informed consent and/or assent to participate in the study before inclusion in the study.

Exclusion (5)

- Patients who have a contraindication to dupilumab according to the approved prescribing information label.
- Any condition that the treating physician or virtual Investigator believes may interfere with the patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from completing the schedule of assessments.
- Patients currently participating in any interventional clinical trial.
- Prior use of dupilumab within 6 months of the baseline assessment.
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (1 total)

Virtual Research Coordination Center, Wilmington, North Carolina, United States

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.